PSMA-Targeted Conjugates with Labile Linkers for Lower Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer, such as doxorubicin, suffer from significant toxicities and lack specificity, leading to off-target effects and reduced efficacy.
Innovation Solution
Development of PSMA-targeted conjugate compounds that selectively deliver therapeutic agents, like doxorubicin and monomethyl auristatin E, to prostate cancer cells using protease- or acid-labile linkers, enhancing tumor targeting and reducing off-target toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments like doxorubicin are used, then cancer cell killing activity is achieved, but significant toxicities and off-target effects occur
Solution Approach 1:
The treatment system is segmented into three functional components: (1) PSMA-targeting moiety for selective cancer cell recognition, (2) protease- or acid-labile linker for controlled drug release, and (3) therapeutic agent for cancer cell killing. This segmentation allows each component to perform its specific function independently, achieving targeted efficacy while minimizing off-target toxicity through the selective targeting component.
Solution Approach 2:
The protease- or acid-labile linker acts as an intermediary between the PSMA-targeting moiety and the therapeutic agent. It maintains the stability of the conjugate in circulation while enabling controlled release of the therapeutic agent within the cancer cell through proteolytic or acidic degradation, thus mediating the delivery of the toxic agent specifically to cancer cells to reduce off-target effects.
2Reliability
If non-targeted therapeutic agents are administered, then cancer treatment is achieved, but lack of specificity leads to reduced efficacy and increased toxicity
Solution Approach 1:
The conjugate compound exhibits local quality through its PSMA-targeting moiety that specifically recognizes and binds to PSMA-expressing cancer cells. This creates a localized effect where the therapeutic agent is delivered specifically to cancer cells with PSMA expression, achieving high tumor targeting specificity while maintaining treatment efficacy through the concentrated delivery mechanism.
3Stability of the object's composition
If stable linkers are used in conjugate compounds, then compound stability is improved, but therapeutic agent release is inhibited
Solution Approach 1:
The linker is designed with dynamic properties that change based on the environmental conditions. It remains stable in the circulatory system under neutral pH and lacks proteolytic enzymes, but becomes labile when exposed to the acidic environment or proteases within the cancer cell. This dynamic behavior allows the linker to provide both stability during transport and controlled release upon reaching the target cell.
Solution Approach 2:
The linker's stability is controlled by parameter changes in the cellular environment, specifically pH change from neutral (circulation) to acidic (endosome/lysosome) and the presence/absence of proteolytic enzymes. This parameter-driven stability switch enables the conjugate to remain stable during circulation while facilitating therapeutic agent release inside the cancer cell.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PSMA-targeted conjugates demonstrate enhanced uptake and cytotoxicity in prostate cancer cells, reducing off-target toxicity and improving treatment efficacy while minimizing side effects in preclinical models.
Implementation Method 1
protease- or acid-labile linkers
Implementation Method 2
protease- or acid-labile linkers
Data Source
AI summary
PSMA targeted conjugate compounds, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject, methods for identifying cancer cells in a sample are described herein.